Lactobacillus gasseri is a probiotic strain occasionally studied for gastrointestinal health, including conditions like diverticulitis. The rationale for using probiotics in diverticulitis is based on their ability to modulate gut microbiota, reduce inflammation, and enhance mucosal barrier function. However, direct scientific evidence for L. gasseri specifically in the treatment or prevention of diverticulitis is limited.

Most clinical studies on probiotics for diverticular disease have used mixed probiotic formulations or other strains such as Lactobacillus casei or Bifidobacterium species. These studies suggest a potential reduction in symptoms and relapse rates, but results are inconsistent and often of low quality. A few studies have evaluated the general use of probiotics in diverticular disease, hinting at possible benefits in reducing inflammation and improving symptoms, but they rarely single out L. gasseri.

Thus, while the theoretical basis for probiotic use (including L. gasseri) in diverticulitis exists—mainly due to their anti-inflammatory and microbiota-modulating properties—robust clinical trials specifically supporting L. gasseri for diverticulitis are lacking. Therefore, the scientific evidence is weak (rated 2/5), and more targeted studies are required to establish efficacy and optimal dosing.